The parents of an Indiana teenager have filed a suit in a federal court in the state's Northern District, charging that school officials violated their privacy rights and parental rights by subjecting their daughter to a mental health screening examination without their permission.
The suit is seen as significant because President Bush has promoted a controversial plan to encourage widespread mental health screening for people "of all ages" in the United States (BMJ 2004; 328; 1458) .
The screening programme at the centre of the legal suit, TeenScreen, was endorsed as a "model" programme by President Bush's New Freedom Commission on Mental Health.
The complaint, filed on 19 September, charges that in December 2004 Chelsea Rhoades, then a 15 year old student at Penn High School, Mishawaka, was told after she took the TeenScreen examination that she had obsessive compulsive disorder and social anxiety disorder.
Chelsea has spoken out against the screening and, with her parents, alleges in the complaint that "a majority" of the students "subjected to TeenScreen" with her were also told they had "some mental or psychological disorder."
The Rhoades family charges that TeenScreen test results "are highly subjective" and that "there is a lack of evidence that the screening actually results in a decreased risk of suicide attempts."
The programme is currently in use at 424 sites in 43 states, the press release says. The money was made available under the Garrett Lee Smith Memorial Act, which President Bush signed into law in October 2004 to promote programmes to prevent suicide in young people.
Columbia University's TeenScreen, which urges "universal" voluntary screening for all teenagers, has come under fire for offering free cinema passes and other inducements to teenagers in the hope of encouraging them to return parental consent forms (BMJ 2005; 331:592 (17 Sep) ).
The programme has also been criticised by the Rutherford Institute, a non-profit civil liberties organisation, for using "passive consent," in which only parents who do not want to have their children screened have to sign a form and send it in to the school. If the school does not receive a form, it is assumed that the parents do not object.
Laurie Flynn, national programme director of TeenScreen, said that only 15% to 20% of schools use passive screening and that the choice to require the active consent of parents was left up to local schools. "We name active consent a preferred best practice, we train applicants to use it, and we offer templates to assist them in doing so. [But] in some school districts passive consent is the norm for all student health activities," she said. Antidepressants should be considered for treating children or young people with moderate to severe depression only in combination with concurrent psychological therapy and with careful monitoring for side effects, and they should not be used at all in children with mild depression. These are among the recommendations of a clinical guideline published this week for the NHS in England and Wales.
"The guideline makes it clear that medication is not the first line treatment for children and young people with depression. Antidepressants should only be considered when psychological treatments are not working, and should only be used in combination with a psychological treatment," explained David Cottrell, professor of child and adolescent psychiatry at the University of Leeds.
Professor Cottrell was a member of the group that developed the guideline for the National Institute for Health and Clinical Excellence (NICE) and the National Collaborating Centre for Mental Health.
Once depression has been diagnosed and assessed, the guideline recommends that children and young people with moderate to severe depression should be offered a specific psychological therapy, such as cognitive behaviour therapy, interpersonal therapy, or family therapy.
Fluoxetine was recommended as the only antidepressant for which trials show that its benefits outweigh the risks, with sertraline or citalopram recommended as second line treatments. The guideline cautioned that paroxetine and venlafaxine, tricyclic antidepressants, and St John's wort should not be used in children or young people. 
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